Search

Chlorphenesin

Human botulinum neurotoxin A/B immune globulin

to more serious symptoms such as respiratory arrest and flaccid paralysis. … As these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle tone (e.g. constipation, ptosis, feeding difficulties) which may progress

Gepirone

Although earlier clinical trials showed promising results for gepirone, its formulation as an immediate-release tablet necessitates frequent administration due to the short half-lives. … novel class of antidepressants that selectively targets the 5HT_1A receptors, thus possessing a more favorable side effects profile with comparable incidence of sexual dysfunction side effects as

Pegloxenatide

Pegloxenatide is under investigation in clinical trial NCT05172999 (Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia).

Floxuridine

Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution.

Imiglucerase

Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human ...

Opaganib

Opaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered.

Tepotinib

[A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is … Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February

EDP1815

investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as

Recombinant Bacterial ACE2 Receptors-like Enzyme

B38-CAP is structured as a carboxypeptidase and derived from _Paenibacillus sp._ The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2